FDA flags fractures, cardiovascular risk tied to J&J's canagliflozin

01/9/2013 | Fox Business

The FDA raised concerns about possible stroke and bone-related safety risks tied to Johnson & Johnson's proposed diabetes treatment canagliflozin, or Invokana. An analysis of cardiovascular events showed a numerical imbalance in strokes although it didn't show a greater risk in a combined measure of cardiovascular deaths, hospitalization, strokes and heart attacks, the FDA said. The drug will be reviewed by the FDA's endocrinologic and metabolic drugs advisory committee as part of the approval process.

View Full Article in:

Fox Business

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN